- Home
- POR vs BPMC Comparison
POR vs BPMC Comparison
Compare POR & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- BPMC
- Stock Information
- Founded
- POR 1889
- BPMC 2008
- Country
- POR United States
- BPMC United States
- Employees
- POR N/A
- BPMC N/A
- Industry
- POR Electric Utilities: Central
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- BPMC Health Care
- Exchange
- POR Nasdaq
- BPMC Nasdaq
- Market Cap
- POR 4.9B
- BPMC 5.8B
- IPO Year
- POR N/A
- BPMC 2015
- Fundamental
- Price
- POR $44.61
- BPMC $86.95
- Analyst Decision
- POR Hold
- BPMC Buy
- Analyst Count
- POR 10
- BPMC 22
- Target Price
- POR $47.63
- BPMC $124.29
- AVG Volume (30 Days)
- POR 1.2M
- BPMC 1.0M
- Earning Date
- POR 04-25-2025
- BPMC 05-01-2025
- Dividend Yield
- POR 4.50%
- BPMC N/A
- EPS Growth
- POR 29.18
- BPMC N/A
- EPS
- POR 3.01
- BPMC N/A
- Revenue
- POR $3,440,000,000.00
- BPMC $508,824,000.00
- Revenue This Year
- POR N/A
- BPMC $45.43
- Revenue Next Year
- POR $4.25
- BPMC $32.80
- P/E Ratio
- POR $14.75
- BPMC N/A
- Revenue Growth
- POR 17.69
- BPMC 104.04
- 52 Week Low
- POR $40.05
- BPMC $80.68
- 52 Week High
- POR $49.85
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- POR 55.05
- BPMC 38.49
- Support Level
- POR $42.41
- BPMC $86.99
- Resistance Level
- POR $45.36
- BPMC $93.04
- Average True Range (ATR)
- POR 0.76
- BPMC 3.24
- MACD
- POR -0.13
- BPMC 0.13
- Stochastic Oscillator
- POR 67.46
- BPMC 1.78
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.